Tibotec begins hepatitis C patient enrollment

[Guest guest]

Tibotec begins hepatitis C patient enrollment

21 Nov 2008

Clinical Research

& (J & J) company Tibotec has begun enrolling patients on to a

clinical study of a potential hepatitis C treatment.

The phase-three trial will assess the investigational protease inhibitor

telaprevir in patients with chronic genotype-one hepatitis C virus for whom the

current standard of treatment has not been successful.

It will be conducted at more than 50 sites across Europe.

" The phase-three trial will give us essential information about the safety and

efficacy of a telaprevir-based regimen in patients who otherwise would have no

recourse when standard treatment fails, " said Pomerantz, president of

Tibotec research and development.

He indicated that the firm looks forward to a point at which it will be able to

gain approval for the treatment and make it available to patients.

Meanwhile Tibotec has announced results from a phase-two trial of another

potential hepatitis C treatment, a compound known as TMC435.

According to the firm, data had demonstrated the safety and efficacy of the

treatment.

[Guest guest]

Tibotec begins hepatitis C patient enrollment

21 Nov 2008

Clinical Research

& (J & J) company Tibotec has begun enrolling patients on to a

clinical study of a potential hepatitis C treatment.

The phase-three trial will assess the investigational protease inhibitor

telaprevir in patients with chronic genotype-one hepatitis C virus for whom the

current standard of treatment has not been successful.

It will be conducted at more than 50 sites across Europe.

" The phase-three trial will give us essential information about the safety and

efficacy of a telaprevir-based regimen in patients who otherwise would have no

recourse when standard treatment fails, " said Pomerantz, president of

Tibotec research and development.

He indicated that the firm looks forward to a point at which it will be able to

gain approval for the treatment and make it available to patients.

Meanwhile Tibotec has announced results from a phase-two trial of another

potential hepatitis C treatment, a compound known as TMC435.

According to the firm, data had demonstrated the safety and efficacy of the

treatment.